Navigation Links
Point Therapeutics Announces Preclinical Data Presentations at,Upcoming American Association of Cancer Research Annual Meeting

BOSTON--(BUSINESS WIRE)--Apr 13, 2007 - Point Therapeutics, Inc. (NASDAQ: POTP) today reported the upcoming presentation of preclinical data at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) taking place in Los Angeles, California, April 14-18, 2007. The AACR poster presentations report on preclinical studies on talabostat's novel mechanism of action.

Additional details for the AACR presentations are as follows:

Presentation Date and Time: Monday, April 16, 2007, 8:00 AM -12:00 PM PT

Abstract #1894: Immune mechanisms of action of talabostat: a dipeptidyl peptidase targeted anti-tumor agent

Presentation Date and Time: Wednesday, April 18, 2007, 8:00 AM -12:00 PM PT

Abstract #5622: The anti-tumor potential of inhibitors of the DASH proteases in a mouse model of human breast cancer

The posters associated with the abstracts will be available on the Point Therapeutics' web site at immediately following their presentation.

About Point Therapeutics, Inc.:

Point is a Boston-based biopharmaceutical company currently studying its lead product candidate, talabostat, in two Phase 3 double blind, placebo-controlled trials in non-small cell lung cancer and in a Phase 2 trial in combination with gemcitabine in metastatic pancreatic cancer. Point has also studied talabostat in several Phase 2 trials, including as a single-agent in metastatic melanoma, in combination with cisplatin in metastatic melanoma and in combination with rituximab in advanced chronic lymphocytic leukemia.


Point Therapeutics, Inc.
Sarah Cavanaugh, 617-933-7508
Director, Corporate Communications


Page: 1

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Analyzers Offer Point-of-Care Lipid Panels
3. Hemoglobin Testing at the Point of Care
4. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
5. New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk
6. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
7. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
10. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
11. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
Post Your Comments:
(Date:11/30/2015)... 2015 --> --> ... Market by Product (Soft Tissue, All Tissue, Dental Welding Lasers), ... and Geography - Global Forecast to 2020", published by MarketsandMarkets, ... a CAGR of 5.2% during the forecast period from 2015 ... and 62 Figures spread through 167 P ages and ...
(Date:11/30/2015)... ST. LOUIS , Nov. 30, 2015  Premera ... today announced an early renewal of the companies, long-standing ... will now extend through at least 2019. ... pharmacy benefit manager capabilities during a competitive review and ... offer the best health plan integration and deliver the ...
(Date:11/30/2015)... 2015 Booth #4303 – The Imaging Components business ... a broader array of products in a new booth (#4303) ... North America in Chicago ... feature X-ray components "At the Heart of Imaging." Products will ... from Varian,s Claymount brand, and computer-aided diagnostic software from MeVis ...
Breaking Medicine Technology:
(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... two new additions to its industry-leading suite of automated breast density assessment ... North America (RSNA) meeting, November 29-December 4, 2015 (South Hall booth #2377). ...
(Date:11/30/2015)... ... 2015 , ... Holcomb – Kreithen Plastic Surgery and ... in Florida, is proud to announce that Dr. Joshua Kreithen, one of its ... a Johnson & Johnson Company. , Ethicon is a global medical device company ...
(Date:11/30/2015)... ... ... The successful filing of an Investigational New Drug application (IND) is a ... key industry segment, Regis Technologies has decided to sponsor and participate in an XTalks-hosted ... , Federal law does not allow new drugs to cross state lines until it ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... the assets of DataTrade Solutions Inc., a Healthcare IT consulting, development and support ... the programming and technical experience available within DataTrade to extend the services currently ...
(Date:11/30/2015)... ... 2015 , ... GKhair & Tibolli team members and artists were excited and ... November 8th and 9th at the Puerto Rico Convention Center, San Juan Puerto Rico. ... top of the line fashion journalists. The San Juan Beauty Show carries immense credibility ...
Breaking Medicine News(10 mins):